logo
Share SHARE
FONT-SIZE Plus   Neg

ViroPharma Shares Plunge As Vancocin Goes Generic

ViroPharma Inc. (VPHM) Tuesday said the U.S. Food and Drug Administration has denied its petition related to its Vancocin capsules, with the agency approving three generic versions of the drug. Exton, Pennsylvania-based ViroPharma said it would seek an injunction to suspend FDA's approval of three generic versions of Vancocin.

The news sent ViroPharma shares plunging 20 percent on the Nasdaq.

Also on Tuesday, Akorn Inc. (AKRX) and Watson Pharmaceuticals Inc. (WPI) revealed that FDA approved each of theirs abbreviated new drug application for vancomycin hydrochloride USP capsules, the generic version of Vancocin. Vancocin is used for the treatment of Clostridium difficile-associated diarrhea, or CDAD, and also for enterocolitis, an inflammation of the colon and small intestine.

Both, Akorn and Watson said they have started shipping the generic version of Vancocin, which, according to IMS Health, generated sales of about $328 million in the US for twelve months ended December 31, 2011.

For the past five years, ViroPharma has been fighting with FDA over the agency's proposal to change the evaluation process and approval guidelines used to approve generic drugs.

ViroPharma believes that FDA has erred in interpreting its bioequivalence regulations in a manner that provides it with broad discretion to permit in vitro bioequivalence testing in the absence of a waiver of in vivo testing.

ViroPharma revealed that the FDA also refused its bid to extend the market exclusivity of Vancocin by an additional three years. The company had filed a supplemental new drug application for Vancocin. FDA said in order for an old antibiotic such as Vancocin to be eligible for a grant of exclusivity, it must be a significant new use or indication.

Additionally, ViroPharma also said it has been notified that the Federal Trade Commission is conducting an investigation whether it has engaged in unfair trade methods with respect to Vancocin. The company said it does not believe that it has engaged in unfair methods of competition and intends to cooperate with the investigation.

VPHM is currently trading at $22.85, down 20.13%, on a volume of 12.5 million shares, far above the three-month average volume of 1.1 million.

AKRX is currently trading on the Nasdaq at $11.88, up 1.71%, while Watson Pharmaceuticals is trading on the NYSE at $66.21, down 0.57%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Target Corp. said it now plans to remodel more of its existing supercenters and open smaller stores in cities, aiming to win back shoppers in the highly competitive retail world. By the end of 2020, the company plans to remodel more than 1,000 of its 1,800 existing stores. Senate Republicans appear poised to approve a budget resolution that will serve as the legislative vehicle for their tax reform plan. The non-binding budget resolution unlocks the reconciliation process, allowing Republicans to pass their tax reform plan with a simple 51-vote majority in the Senate. President Donald Trump intends to nominate antitrust attorney Joseph Simons as chairman of the Federal Trade Commission, the White House announced on Thursday. Simons, who served as an FTC official under President George W. Bush, is currently a partner and co-chair of the antitrust group at law firm Paul Weiss.
comments powered by Disqus
Follow RTT